Another member of the CYP2C subfamily, CYP2C19, metabolizes drugs used in the treatment of malaria, HIV/AIDS, depression and thromboembolic diseases and genetic variants have been implicated in ADRs and treatment failure [9]. Here, CYP2C19 is linked to Thromboembolism.